mardi 13 février 2018

Onco Actu du 13 février 2018

1. Biologie

On the trail of invasive cells in breast cancer [Nature]

3.1.1 Prévention - Tabac - e-cigs

Balancing the benefits and risks of electronic cigarettes [Mass. General Hospital]

3.6 Prévention - Activité physique

Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum Proceedings of a Workshop (2018) [National Academies Press]

4.2 Dép., diag. & prono. - Génome

Rewriting Life 2017 was the year consumer DNA testing blew up [MIT Technology Review]

5. Traitements

The Drug Development Paradigm in Oncology Proceedings of a Workshop (2018) [National Academies Press]

5.1 Traitements - Pré-clinique

Cancer-fighting nanorobots seek and destroy tumors [Arizona State University]

DNA Robots Target Cancer [The Scientist]

5.10 Traitements - Essais

Soft chemotherapy is very effective in older patients when added to targeted treatment in an aggressive breast cancer subtype [EORTC]

5.12 Immunothérapies

Smart bomb virus shows promise as brain tumor immunotherapy [MD Anderson Cancer Center]

Newly identified potential therapeutic approach kills triple-negative breast cancer cells in pre-clinical study [MD Anderson Cancer Center]

Execs Talk Hurdles As Immunotherapy Combos, CAR-T Launches Progress [Xconomy]

5.12.5 Immunothérapies - Pharma

France's Cellectis wins U.S patents for gene editing technology [Reuters]

5.2 Pharma

U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib [Pfizer]

Janssen Submits Marketing Authorisation Application for Apalutamide to Treat Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer [Janssen]

5.2.3 Pharma - économie

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma [Aveo]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves Targeted Radiotherapy for Neuroendocrine Tumors [Cancer Research Catalyst]

5.4 Traitements - Economie

NICE backs EUSA’s kidney cancer drug Fotivda [PharmaTimes]

Analysis: Trump budget tries to address drug prices, but leaves list prices untouched [STAT]

Contribution of NIH funding to new drug approvals 2010–2016 [PNAS]

NIH funding contributed to 210 approved drugs in recent years, study says [STAT]

5.5 ASCO

Web-Based Intervention Helps Kids Stay Physically Active After Cancer Treatment [ASCO]

Therapeutic Sexual Aids Frequently Not Available for Cancer Survivors Who Need Them [ASCO]

Many Young Adult Cancer Survivors Do Not Seek Follow-up Care After Treatment Ends [ASCO]

Exercise Speeds Improvement in Arm Mobility After Surgery for Breast Cancer [ASCO]

Exercising During Chemotherapy for Breast or Colon Cancer Has Long-Term Benefits [ASCO]

6.1 Observation

Obesity associated with longer survival for men with metastatic melanoma [MD Anderson Cancer Center]

6.10.1 Politiques (USA)

NIH stays flat, absorbs three institutes in president’s 2019 budget proposal [Science]

A Better Way to Provide a 'Right to Try' [Bloomberg]

6.6 Publications

Researchers debate whether journals should publish signed peer reviews [Science]

6.9 Controverses

Few UK universities have adopted rules against impact-factor abuse [Nature]